 that several sodium glucose
cotransporter-2 (SGLT-2) inhibitors and glucagon like
peptide 1 receptor (GLP-1) agonists, which were originally
developed to lower blood glucose levels, can also have
beneﬁcial cardiovascular effects in persons with type 2
diabetes.21 These effects are independent of their blood
glucose lowering effect. To what extent this beneﬁt can
also be observed in those with type